Biogen (BIIB) is back in the spotlight after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, alongside encouraging Phase 3 lupus data for dapirolizumab pegol presented with partner UCB.

The recent FDA Breakthrough Therapy Designation for salanersen and positive lupus data arrive as Biogen’s share price trades at US$195.34, with a 1-year total shareholder return of 45.61% contrasting with weaker 3 and 5 year total shareholder returns. This suggests rebuilding momentum after a tougher multi year period.

If this kind of late stage pipeline progress interests you, it can be worth seeing what else is lining up in healthcare AI, starting with 38 healthcare AI stocks.

With Biogen trading at US$195.34 after a 45.61% 1 year total return but weaker 3 and 5 year results, plus an indicated intrinsic discount of 55.45%, are you looking at a genuine opportunity, or a stock already pricing in future growth?

Most Popular Narrative: 10.9% Undervalued

Biogen's most followed narrative pegs fair value around $219.27 compared with the last close at $195.34, framing the recent share price strength as still short of that intrinsic estimate.

Demand for Biogen's Alzheimer's therapy LEQEMBI is described as poised for structural long-term growth, supported by a rapidly aging global population and accelerating rates of mild cognitive impairment diagnoses facilitated by breakthroughs in blood-based biomarkers and expanding diagnostic infrastructure. These factors are viewed as positioning Biogen to capture a larger patient pool and drive sustained revenue expansion.

Curious what has to happen for that gap to close? The narrative leans on measured revenue growth, higher margins, and a richer future earnings multiple. The exact mix of those moving parts is where things get interesting.

Based on this narrative, analysts blend moderate top line growth, improving profitability and a specific discount rate of 7.49% to reach a fair value estimate of about $219.27, which is above both the current $195.34 share price and Biogen's own earlier fair value estimate of about $205.67.

Result: Fair Value of $219.27 (UNDERVALUED)

However, this hinges on a few therapies. Any clinical or reimbursement setbacks for LEQEMBI, SKYCLARYS or ZURZUVAE could quickly challenge that 10.9% undervalued thesis.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: What The P/E Says

That 10.9% “undervalued” narrative sits alongside a different message from the P/E. At about 21x earnings, Biogen trades above the US Biotechs average of 16.6x, yet below a fair ratio of 22.9x and peer average of 26.4x. Is that a margin of safety or a pricing premium you are comfortable with?

Next Steps

Given the mix of optimism around new therapies and the mixed return history, now is the moment to look at the full picture yourself and weigh both sides. You can start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Biogen is on your radar, do not stop there. A few targeted stock lists could help you identify opportunities that fit your style before others notice.

• Spot potential mispricing by scanning companies that combine quality with attractive valuations through the 48 high quality undervalued stocks.
• Build a sturdier core for your portfolio by checking stocks in the solid balance sheet and fundamentals stocks screener (46 results).
• Stay ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.